129 related articles for article (PubMed ID: 34321384)
1. Intestinal Perforation in a Patient with Colon Cancer during Treatment with Regorafenib: A Case Report and Review of the Literature.
Ouchi R; Okada K; Usui K; Kurata N; Suzuki S; Nagao M; Watanabe Y; Koyama K
Tohoku J Exp Med; 2021 Jul; 254(3):207-211. PubMed ID: 34321384
[TBL] [Abstract][Full Text] [Related]
2. Gastrointestinal perforation during regorafenib administration in a case with hepatic metastases of colon cancer.
Ogata K; Takamori H; Umezaki N; Yagi T; Ogawa K; Ozaki N; Hayashi H; Tanaka H; Ikuta Y; Doi K
J Chemother; 2017 Oct; 29(5):314-316. PubMed ID: 27438692
[TBL] [Abstract][Full Text] [Related]
3. Regorafenib use as a possible cause of intestinal perforation.
Adenis A; Kotecki N; Decanter G; Clisant S; Penel N
Acta Oncol; 2013 Nov; 52(8):1789-90. PubMed ID: 24024697
[No Abstract] [Full Text] [Related]
4. Intestinal perforation after regorafenib usage.
Sarıcı B; Karakaş S; Uylas U; Aktaş A; Dikilitaş M; Kayaalp C
Turk J Gastroenterol; 2018 Mar; 29(2):245-247. PubMed ID: 29749339
[No Abstract] [Full Text] [Related]
5. Intestinal Perforation in a patient with peritoneal carcinomatosis from colon cancer treated with Regorafenib. Description of a case and review of the literature.
Bellia MA; Sofia C; Marino MA; Mazzeo C; Biondo SA; Cucinotta E; Fleres F
Radiol Case Rep; 2024 May; 19(5):2013-2019. PubMed ID: 38449482
[TBL] [Abstract][Full Text] [Related]
6. [Corneal perforation with tyrosine kinase inhibitor chemotherapy: REGORAFENIB].
Lanfant L; Trone MC; Garcin T; Gauthier AS; Thuret G; Gain P
J Fr Ophtalmol; 2021 Apr; 44(4):544-548. PubMed ID: 33612324
[TBL] [Abstract][Full Text] [Related]
7. The safety of regorafenib for the treatment of gastrointestinal stromal tumors.
Rutkowski P; Stępniak J
Expert Opin Drug Saf; 2016 Jan; 15(1):105-16. PubMed ID: 26651387
[TBL] [Abstract][Full Text] [Related]
8. [A case of erythema multiforme induced by regorafenib therapy for metastatic colon cancer].
Mii Y; Fukuoka E; Murata K; Otsubo D; Sawa H; Oka S; Iwatani Y; Kuroda D
Gan To Kagaku Ryoho; 2014 Nov; 41(12):1841-3. PubMed ID: 25731348
[TBL] [Abstract][Full Text] [Related]
9. Regorafenib-associated hand-foot skin reaction: practical advice on diagnosis, prevention, and management.
McLellan B; Ciardiello F; Lacouture ME; Segaert S; Van Cutsem E
Ann Oncol; 2015 Oct; 26(10):2017-26. PubMed ID: 26034039
[TBL] [Abstract][Full Text] [Related]
10. Regorafenib: a novel multitargeted tyrosine kinase inhibitor for colorectal cancer and gastrointestinal stromal tumors.
Crona DJ; Keisler MD; Walko CM
Ann Pharmacother; 2013 Dec; 47(12):1685-96. PubMed ID: 24259629
[TBL] [Abstract][Full Text] [Related]
11. Concurrent gastrointestinal perforation and pulmonary embolism due to bevacizumab in an adult undergoing treatment for stage IV colon cancer.
Qureshi S; Elliott RB; Herrington JD
J Oncol Pharm Pract; 2017 Dec; 23(8):625-628. PubMed ID: 27604142
[TBL] [Abstract][Full Text] [Related]
12. Prevention and management of adverse events related to regorafenib.
De Wit M; Boers-Doets CB; Saettini A; Vermeersch K; de Juan CR; Ouwerkerk J; Raynard SS; Bazin A; Cremolini C
Support Care Cancer; 2014 Mar; 22(3):837-46. PubMed ID: 24337717
[TBL] [Abstract][Full Text] [Related]
13. Regorafenib-induced hyperammonemic encephalopathy.
Kuo JC; Parakh S; Yip D
J Clin Pharm Ther; 2014 Aug; 39(4):446-8. PubMed ID: 24707992
[TBL] [Abstract][Full Text] [Related]
14. Multikinase inhibitor regorafenib inhibits the growth and metastasis of colon cancer with abundant stroma.
Takigawa H; Kitadai Y; Shinagawa K; Yuge R; Higashi Y; Tanaka S; Yasui W; Chayama K
Cancer Sci; 2016 May; 107(5):601-8. PubMed ID: 26865419
[TBL] [Abstract][Full Text] [Related]
15. Bevacizumab-induced intestinal perforation in a patient with inoperable breast cancer: a case report and review of the literature.
Fujii Y; Hirahara N; Kaji S; Taniura T; Hyakudomi R; Yamamoto T; Tajima Y
J Med Case Rep; 2018 Mar; 12(1):84. PubMed ID: 29580267
[TBL] [Abstract][Full Text] [Related]
16. Bilateral sensorineural hearing loss induced by regorafenib.
Cheng J; Wang L; Zhu LN; Wang L
J Clin Pharm Ther; 2019 Dec; 44(6):963-965. PubMed ID: 31381817
[TBL] [Abstract][Full Text] [Related]
17. Associations among regorafenib concentrations, severe adverse reactions, and ABCG2 and OATP1B1 polymorphisms.
Maeda A; Irie K; Ando H; Hasegawa A; Taniguchi H; Kadowaki S; Muro K; Tajika M; Aoki M; Inaguma K; Kajita M; Fujimura A; Fukushima S
Cancer Chemother Pharmacol; 2019 Jan; 83(1):107-113. PubMed ID: 30368586
[TBL] [Abstract][Full Text] [Related]
18. Single dose regorafenib-induced hypertensive crisis.
Yilmaz B; Kemal Y; Teker F; Kut E; Demirag G; Yucel I
Exp Oncol; 2014 Jun; 36(2):134-5. PubMed ID: 24980770
[TBL] [Abstract][Full Text] [Related]
19. Regorafenib: A Review of Its Use in Patients with Advanced Gastrointestinal Stromal Tumours.
Shirley M; Keating GM
Drugs; 2015 Jun; 75(9):1009-17. PubMed ID: 25998375
[TBL] [Abstract][Full Text] [Related]
20. Acute Liver Failure Due to Regorafenib May Be Caused by Impaired Liver Blood Flow: A Case Report.
Akamine T; Ando K; Oki E; Saeki H; Nakashima Y; Imamura YU; Ohgaki K; Maehara Y
Anticancer Res; 2015 Jul; 35(7):4037-41. PubMed ID: 26124352
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]